NCT04136756 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

April 24, 2023

Study Completion Date

April 24, 2023

Conditions

Multiple MyelomaNon-Hodgkin LymphomaIndolent Non-Hodgkin Lymphoma

Interventions

DRUG

NKTR-255

NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability

DRUG

NKTR-255 Q21

NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability

DRUG

Rituximab

Rituximab administered intravenously at specified dose on specified days

DRUG

Daratumumab

Daratumumab administered subcutaneously at specified dose on specified days

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center, New York

10595

New York Medical College, Valhalla

22031

Virginia Cancer Specialists, Fairfax

27705

Duke University Health System, Durham

30322

Winship Cancer Institute, Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

48109

University of Michigan, Ann Arbor

55455

University of Minnesota, Minneapolis

77030

MD Anderson Cancer Center, Houston

85338

Western Regional Medical Center - CTCA, Goodyear

91010

City of Hope, Duarte

94143

University of California, San Francisco, San Francisco

98109

University of Washington, Seattle